北陸藥業:獲釓貝葡胺注射液註冊批件
格隆匯2月11日丨北陸藥業(300016.SZ)公佈,近日,公司收到國家藥品監督管理局下發的釓貝葡胺注射液《藥品註冊批件》。
藥品名稱:釓貝葡胺注射液;劑型:注射劑;規格:10ml:5.290g釓貝葡胺(相當於釓貝酸3.340g,葡甲胺1.950g);註冊分類:原化學藥品第6類;藥品有效期:18個月;藥品批准文號有效期:至2025年1月14日。
釓貝葡胺注射液為國家醫保乙類品種,是一種用於診斷性磁共振成像(MRI)的順磁性對比劑。
取得釓貝葡胺注射液註冊批件後,公司的對比劑系列產品增至六個品種,其對公司進一步優化對比劑產品結構、提升市場競爭力有着積極影響。公司將積極開展新產品上市的各項準備工作,並及時將產品推向市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.